NantPharma specializes in the development and manufacturing of superior quality, injectable pharmaceuticals. It is committed to a fully-integrated platform delivering the highest-quality products that are uniquely positioned to enhance patient care. In 2009, Dr. Patrick Soon-Shiong established research, development and manufacturing capabilities through the NantWorks portfolio of companies, which are focused on healthcare transformation through the convergence of a wide range of scientific discoveries, research and technologies. Rapid growth in the Company in 2012 led to a financial investment in NantPharma by The Blackstone Group. Blackstone is a premier global investment and advisory firm which strives to provide solutions to create lasting value for its investors, the companies in which they invest and society at large. NantPharma is headquartered in Lincolnshire, Illinois with a manufacturing facility in Oelwein, Iowa and a research and development lab in the Chicagoland area. NantPharma currently manufactures and markets crude heparin in a concentrated eluate form, processed from porcine intestinal mucosa that is collected exclusively from slaughterhouses in the United States and Europe.